Skip banner Home   Sources   How Do I?   Site Map   What's New   Help  
Search Terms: medicare prescription drug
  FOCUS™    
Edit Search
Document ListExpanded ListKWICFULL format currently displayed   Previous Document Document 265 of 532. Next Document

Copyright 2002 The Tribune Co. Publishes The Tampa Tribune  
The Tampa Tribune

April 23, 2002, Tuesday, FINAL EDITION

SECTION: BAYLIFE, Pg. 3

LENGTH: 597 words

HEADLINE: What's Ahead For Medicare Drug Benefits?

BYLINE: LINDSAY PETERSON, lpeterson@tampatrib.com

BODY:
Expect a lot of talk about Congress passing a Medicare prescription drug benefit this year. Don't expect much action.

That was the consensus of experts who spoke earlier this month at the American Society on Aging/ National Council on Aging conference in Denver.

No one disagrees that seniors need help. The Congressional Budget Office estimates people on Medicare will spend nearly $1.8 trillion of their own money on medication in the next decade.

But officials can't agree how to help. There's an ideological debate swirling about whether prescriptions should be handled as a traditional Medicare benefit, managed by the government, our through private insurance.

Most seniors don't care about this as long as they're covered, according to Howard Bedlin of the National Council on Aging.

The big obstacle is money.

Falling Short

President Bush has proposed spending $190 billion over 10 years on Medicare changes. The most generous congressional proposal would spend more than twice as much, yet the coverage would still be spotty, Bedlin said.

His NCOA designed a mock program costing about $500 billion over 10 years and presented it to a group of seniors for their opinions. Even at that funding level, only one-third said they would buy it; out-of-pocket premium and deductible costs were too high.

Guess what it would cost to set up a program that would provide drug benefits comparable to what House and Senate members get? About $800 billion over the 10 years. "Congress is simply not putting up the money," Bedlin said - even though the government could find it, in his view, by looking no further than promised federal tax cuts.

Addressing Demand

It's a question of priorities, agreed Jeanette Takamura, former head of the U.S. Administration on Aging, now a professor at California State University in Los Angeles.

"Congress will say, "We know what you want, but look at the world. We've got to make sure we win this war.' But those two issues are not exclusive," she said at the conference. "People must stand up and say, "We must have prescription drugs as a benefit.' "

The emerging drug card programs and the minimal Bush proposal, aimed at helping the poor, might even do more harm than good, said Donna Yee, an expert on aging with the Asian Community Center in California.

"All these little proposals, these little programs, erode any groundswell for change," she said. "People running for office will say, "Look what we've done.' And the [voters] will think they've accomplished something. ... But it's not enough."

Larry Polivka, of the Florida Policy Exchange Center on Aging at the University of South Florida, on the panel with Yee and Takamura, disagreed. People aren't fooled by meager programs, he said, and demand for a comprehensive prescription drug benefit is building.

In the meantime, older people with no drug coverage will have to get by on what's available.

Pfizer Inc. has a program for low-income seniors; call 1-800-717-6005. So does Eli Lilly and Co., 1-877-795-4559, and Novartis Pharmaceuticals, 1-866-974-2273.

Seven drug companies, including Abbott Laboratories and
GlaxoSmithKline, recently announced a new discount program called Together Rx. For information, call 1-800-865-7211.

The Robert Wood Johnson Foundation helps people find drug discounts at www.rxassist.orgonline. Another helpful site is www.needymeds.com

For more advice, try SHINE, Serving Health Insurance Needs of Seniors, at 1-800-963-5337. Ask for its "prescription assistance" fact sheet.

NOTES: LINDSAY PETERSON PRIME TIME

LOAD-DATE: April 24, 2002




Previous Document Document 265 of 532. Next Document
Terms & Conditions   Privacy   Copyright © 2003 LexisNexis, a division of Reed Elsevier Inc. All Rights Reserved.